Telormedix's Series B - II Round

Telormedix raised a round of funding on December 02, 2013.

Telormedix is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company's lead product, TMX-101, is c…

Articles about Telormedix's Series B - II Round: